Merus N.V. (MRUS): Price and Financial Metrics

Merus N.V. (MRUS): $13.85

-0.96 (-6.48%)

POWR Rating

Component Grades













Add MRUS to Watchlist
Sign Up

Industry: Biotech



in industry


  • MRUS scores best on the Sentiment dimension, with a Sentiment rank ahead of 71.08% of US stocks.
  • The strongest trend for MRUS is in Stability, which has been heading up over the past 179 days.
  • MRUS ranks lowest in Momentum; there it ranks in the 4th percentile.

MRUS Stock Summary

  • Of note is the ratio of Merus NV's sales and general administrative expense to its total operating expenses; merely 13.39% of US stocks have a lower such ratio.
  • For MRUS, its debt to operating expenses ratio is greater than that reported by merely 7.68% of US equities we're observing.
  • MRUS's price/sales ratio is 23.71; that's higher than the P/S ratio of 93.68% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Merus NV are CALA, MIRM, CRUS, FULC, and APTX.
  • Visit MRUS's SEC page to see the company's official filings. To visit the company's web site, go to

MRUS Valuation Summary

  • In comparison to the median Healthcare stock, MRUS's price/sales ratio is 589.47% higher, now standing at 26.2.
  • MRUS's price/sales ratio has moved down 39.5 over the prior 64 months.
  • MRUS's EV/EBIT ratio has moved down 3.7 over the prior 64 months.

Below are key valuation metrics over time for MRUS.

Stock Date P/S P/B P/E EV/EBIT
MRUS 2021-08-31 26.2 4.6 -11.3 -8.0
MRUS 2021-08-30 26.1 4.6 -11.3 -7.9
MRUS 2021-08-27 26.7 4.7 -11.5 -8.2
MRUS 2021-08-26 25.9 4.5 -11.2 -7.8
MRUS 2021-08-25 25.2 4.4 -10.9 -7.5
MRUS 2021-08-24 24.5 4.3 -10.6 -7.2

MRUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MRUS has a Quality Grade of D, ranking ahead of 21.68% of graded US stocks.
  • MRUS's asset turnover comes in at 0.127 -- ranking 244th of 682 Pharmaceutical Products stocks.
  • ACUR, ABBV, and KMPH are the stocks whose asset turnover ratios are most correlated with MRUS.

The table below shows MRUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.127 1 -1.828
2021-06-30 0.125 1 -4.520
2021-03-31 0.120 1 -2.933
2020-12-31 0.132 1 -2.684
2020-09-30 0.122 1 -2.459
2020-06-30 0.124 1 -1.944

MRUS Price Target

For more insight on analysts targets of MRUS, see our MRUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.71 Average Broker Recommendation 1.25 (Strong Buy)

MRUS Stock Price Chart Interactive Chart >

Price chart for MRUS

MRUS Price/Volume Stats

Current price $13.85 52-week high $33.09
Prev. close $14.81 52-week low $13.74
Day low $13.74 Volume 275,095
Day high $14.86 Avg. volume 195,046
50-day MA $22.28 Dividend yield N/A
200-day MA $25.63 Market Cap 603.17M

Merus N.V. (MRUS) Company Bio

Merus B.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. The company was founded in 2003 and is based in Utrecht, Netherlands.

MRUS Latest News Stream

Event/Time News Detail
Loading, please wait...

MRUS Latest Social Stream

Loading social stream, please wait...

View Full MRUS Social Stream

Latest MRUS News From Around the Web

Below are the latest news stories about Merus NV that investors may wish to consider to help them evaluate MRUS as an investment opportunity.

Merus (MRUS) Receives a Buy from Needham

In a report released today, Ami Fadia from Needham maintained a Buy rating on Merus (MRUS – Research Report), with a price target of $45.00. The company's shares closed last Wednesday at $26.14. According to, Fadia is a 1-star analyst with an average return of -1.6% and a 45.4% success rate. Fadia covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Intra-Cellular Therapies, and ACADIA Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Merus with a $44.67 average price target.

Howard Kim on TipRanks | February 10, 2022

Merus to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences: Guggenheim Healthcare Talks/2022 Oncology Conference (fireside chat): Thursday, February 10 at 10:30-10:55 a.m. ETCiti's 2022

Yahoo | February 3, 2022

Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus

Incyte Corporation (NASDAQ: INCY) is withdrawing the New Drug Application for parsaclisib in relapsed/refractory follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL). Parsaclisib is the Company's next-generation oral inhibitor of phosphatidylinositol 3-kinase delta (PI3Kδ). The decision impacts only the FL, MZL, and MCL indications in the U.S. and does not affect other ongoing clinical trials in the U.S. or other countries. Related: Gilead Withdraws Use Of Zydel

Yahoo | January 26, 2022

Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Shannon Campbell as Executive Vice President & Chief Commercial Officer. Ms. Campbell is an accomplished healthcare leader with demonstrated success leading commercial businesses across a rang

Yahoo | January 25, 2022

We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | January 7, 2022

Read More 'MRUS' Stories Here

MRUS Price Returns

1-mo -35.49%
3-mo -48.26%
6-mo -47.74%
1-year -34.36%
3-year 5.41%
5-year -27.41%
YTD -56.45%
2021 81.40%
2020 24.50%
2019 0.57%
2018 -27.84%
2017 -8.10%

Continue Researching MRUS

Want to see what other sources are saying about Merus NV's financials and stock price? Try the links below:

Merus NV (MRUS) Stock Price | Nasdaq
Merus NV (MRUS) Stock Quote, History and News - Yahoo Finance
Merus NV (MRUS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7282 seconds.